Post-Transplant Cyclophosphamide Allows Allogeneic Hematopoietic Stem-Cell Transplantation Across Donor Types for Nonmalignant Hematologic Diseases.

J Hematol · 2026 · PMC13071939 · PMID 41983154

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Even though the OS, DFS, and GRFS showed a trend in favor of the PTCY cohort, there was no statistically significant difference in these outcomes at 12 months after transplant for the PTCY and CNI-MTX cohorts, perhaps due to the limited sample size.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.